OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!
OutSmart Cancer is the podcast for people who refuse to settle for one-size-fits-all cancer care. Hosted by Dr. Dino Prato, founder of Envita Medical Centers, this show offers expert insight into the world of precision oncology, integrative treatments, and the hidden factors that make cancer so hard to treat — and what to do about them.
Whether you’ve been newly diagnosed, are navigating treatment resistance, or want a second opinion grounded in science and compassion, you’ll hear empowering discussions on:
- DNA, RNA, and immune-based targeting
- The truth behind standard protocols
- What most doctors miss in treatment planning
- Stories of hope from patients who’ve been told “there’s nothing more we can do”
We believe in personalized, data-driven medicine — not protocol-based guessing.
You don’t have to fight cancer blindly. You can OutSmart it.
Disclaimer: This podcast is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before making medical decisions. Results vary and no specific outcomes are guaranteed. Some treatments may not be FDA-approved or available in all locations. Testimonials reflect individual experiences and may not represent typical outcomes. Certain therapies may be offered only at Envita’s international clinic in Hermosillo, Mexico.
OutSmart Cancer - Precision Oncology. Less Guess Work. More Life!
CAR-T vs AAIT: The Secret Benefits and Risks of Cancer Immunotherapy
Immunotherapy is revolutionizing cancer care — but not all immunotherapies are the same.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains the secret benefits and key differences between CAR-T cell therapy and AAIT (Autologous Adoptive Immunotherapy) — and why one approach may offer a safer, more personalized path for solid tumor cancers.
Dr. Prato breaks down how CAR-T therapy works for blood cancers and why it struggles with solid tumors, including the risks of cytokine release syndrome and neurotoxicity. Then he introduces AAIT, a next-generation immune therapy that trains your own natural killer (NK) and dendritic cells using DAMPs (Damage-Associated Molecular Patterns) — your body’s natural danger signals — to identify and destroy tumors more effectively and safely.
🎯 What You’ll Learn in This Episode:
- How CAR-T cell therapy works — and why it’s limited to blood cancers
- The role of NK and dendritic cells in fighting solid tumors
- What DAMPs are and how they supercharge immune recognition
- How AAIT avoids cytokine storms and severe side effects
- Why tumor microenvironment mapping is crucial for lasting results
- How Envita’s precision immunotherapy combines safety and power
📊 In our experience, precision-targeted immunotherapy helps patients rebuild immune strength and achieve higher response rates with fewer side effects compared to traditional treatments.
“Your immune system is powerful — the secret is training it to win.”
Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.
You can read the full peer-reviewed study at:
https://www.scirp.org/journal/paperinformation?paperid=132493